Heidelberg Pharma AG (HPHA) AI Stock Analysis

• Market Cap: €150.52M
• Dividend Yield: N/A
• Average Volume (3M): 5.43K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.53
• Revenue Growth: -24.29%
• EPS Growth: -13.92%
• Country: DE
• Employees: 105
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 46,601,097
• 10 Day Avg. Volume: 7,535
• 30 Day Avg. Volume: 5,428
• PEG Ratio: 0.93
• Price to Book (P/B): 5.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.95
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Heidelberg Pharma AG's financial performance is challenged by declining revenues and significant operating losses, contributing to a low score. Despite strong technical momentum, the valuation is negatively impacted by a lack of profitability. The company needs to address financial and operational issues to improve its overall market position.

Heidelberg Pharma AG Business Overview & Revenue Model

Company Description

Heidelberg Pharma AG (HPHA) is a biotechnology company specializing in the development of innovative therapies for the treatment of cancer. The company is particularly focused on the development of Antibody Targeted Amanitin Conjugates (ATACs), which are a novel class of antibody-drug conjugates. Heidelberg Pharma aims to harness the tumor-targeting capabilities of antibodies combined with the potent cytotoxicity of Amanitin to create effective cancer treatments. The company operates primarily in the biopharmaceutical sector, engaging in research, development, and potential commercialization of its proprietary drug candidates.

How the Company Makes Money

Heidelberg Pharma AG generates revenue through a combination of licensing agreements, collaborations, and partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and potential royalties on sales of successfully commercialized products. The company may also receive research funding from these collaborations to advance its ATAC technology and pipeline. Additionally, Heidelberg Pharma may engage in strategic partnerships to co-develop or out-license its proprietary technologies, thereby expanding its reach and financial potential in the oncology therapeutics market.

Heidelberg Pharma AG Financial Statement Overview

Summary

Heidelberg Pharma AG is experiencing financial challenges with declining revenues, significant operating losses, and negative cash flows. The balance sheet shows some stability, but high liabilities and declining equity may pose future risks. Improvement is needed in operational efficiency and financial structure.

Income Statement

Heidelberg Pharma AG shows decreasing revenue and negative profit margins, with a declining revenue growth rate from recent years. The company struggles with high EBIT and EBITDA losses, indicating operational inefficiencies.

Balance Sheet

The balance sheet displays a moderate debt-to-equity ratio and a reasonable equity ratio. However, the declining stockholders' equity and high total liabilities indicate potential financial instability.

Cash Flow

The company exhibits negative operating and free cash flows, which could affect its liquidity. Free cash flow has been consistently negative, but financing activities provide some cash influx. The ratios indicate challenges in converting revenue into cash.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
6.85M	6.85M	9.86M	18.51M	1.75M	8.49M
	Gross Profit
4.40M	4.20M	6.61M	13.83M	-2.96M	2.89M
	EBIT
-25.63M	-24.56M	-21.21M	-18.33M	-25.63M	-18.56M
	EBITDA
-19.96M	-18.37M	-18.71M	-16.19M	-24.83M	-17.55M
	Net Income Common Stockholders
-20.83M	-19.38M	-20.35M	-19.70M	-26.63M	-18.37M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
20.68M	29.42M	43.44M	81.33M	6.14M	4.98M
	Total Assets
52.81M	60.72M	70.35M	100.58M	21.73M	19.61M
	Total Debt
151.89K	21.97M	5.83M	15.98M	10.63M	202.68K
	Net Debt
-20.53M	-7.45M	-37.61M	-65.35M	4.49M	-4.78M
	Total Liabilities
27.74M	29.85M	21.01M	33.94M	15.03M	6.73M
	Stockholders Equity
25.06M	30.87M	49.34M	66.64M	6.70M	12.88M
Cash Flow		Free Cash Flow
-27.94M	-30.04M	-34.63M	-9.48M	-28.00M	-19.33M
	Operating Cash Flow
-27.42M	-29.59M	-33.67M	-8.86M	-26.61M	-17.89M
	Investing Cash Flow
-527.89K	-449.13K	5.85M	-597.57K	-1.40M	-1.29M
	Financing Cash Flow
16.08M	16.08M	-10.05M	84.00M	29.17M	14.29M

Heidelberg Pharma AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.23
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:HPHA, the sentiment is Positive. The current price of 3.23 is above the 20-day moving average (MA) of 2.97, above the 50-day MA of 2.79, and above the 200-day MA of 2.53, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 70.93 is Negative, neither overbought nor oversold. The STOCH value of 66.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:HPHA.

Heidelberg Pharma AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FME	65 Neutral	€15.08B	24.39	4.37%	2.32%	0.10%	27.83%
BIO3	63 Neutral	€1.44B	44.96	5.13%	0.27%	-18.82%	-113.85%
MRK	59 Neutral	€49.80B	17.93	9.81%	1.92%	0.78%	-1.70%
BAYN	56 Neutral	€22.47B	―	-9.56%	0.48%	-0.92%	-4.30%
HPHA	55 Neutral	€150.52M	―	-59.35%	―	-24.29%	-13.92%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
EVT	48 Neutral	€1.28B	―	-20.51%	―	1.50%	-127.76%